n°204

May 2019

Issue Contents
Editorial

Free  Antibiotics: no market, no interest

p.115

Marketing Authorisations

Lesinurad (Zurampic°) or lesinurad + allopurinol (Duzallo°) in gout

p.117-118
No therapeutic advance over probenecid

INN Common stem: -­profen, ­-­profen­-

p.118

Letermovir (Prevymis°) to prevent cytomegalovirus reactivation

p.119
Different adverse effect profile from that of other anti-CMV drugs

Cenegermin eye drops (Oxervate°) in neurotrophic keratitis

p.120
Efficacy in healing corneal lesions, but no improvement in vision

Free  Dupilumab (Dupixent°) in adults with atopic dermatitis

p.121
An option for very troublesome eczema after failure of ciclosporin

Pentosan polysulfate (Elmiron°) in bladder pain syndrome

p.122-123
A repurposed drug with no proven efficacy that can cause fatal thrombocytopenia

Adverse Effects

Drug-induced retinal disorders

p.124-127

Noscapine: acute abdominal pain

p.128

Angiotensin II receptor antagonists (ARBs): ­psoriasis

p.128

Reviews

Oral antihistamines and pruritus associated with skin disorders

p.129-131
Efficacy only demonstrated in chronic urticaria

Unconjugated pneumococcal vaccine and COPD

p.131-132
Less pneumonia, but no proven effect on risk of hospital admission

Outlook

Vaccine hesitancy: understanding it better, to provide better support

p.133-137

Drugs for Alzheimer's disease: reduction in the number of prescriptions too slow

p.138

Free  Normalisation of school behaviour with methylphenidate

p.139

Masthead

Free  Masthead

p.114

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe